AbCellera Biologics Inc. (ABCL)
Market Cap | 814.53M |
Revenue (ttm) | 35.79M |
Net Income (ttm) | -146.90M |
Shares Out | 294.05M |
EPS (ttm) | -0.52 |
PE Ratio | n/a |
Forward PE | 27.47 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 2,134,955 |
Open | 2.800 |
Previous Close | 2.780 |
Day's Range | 2.700 - 2.800 |
52-Week Range | 2.700 - 8.050 |
Beta | 0.44 |
Analysts | Strong Buy |
Price Target | 17.00 (+513.72%) |
Earnings Date | Aug 6, 2024 |
About ABCL
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic c... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for ABCL stock is "Strong Buy." The 12-month stock price forecast is $17.0, which is an increase of 513.72% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/z/b/conf17-2496214.jpg)
AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024.
![](https://cdn.snapi.dev/images/v1/1/z/conf15-2450537.jpg)
AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024.
![](https://cdn.snapi.dev/images/v1/z/b/press4-2416164.jpg)
AbCellera Reports Q1 2024 Business Results
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q1 2024 Business Results.
![](https://cdn.snapi.dev/images/v1/n/g/press16-2402880.jpg)
AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies.
![](https://cdn.snapi.dev/images/v1/k/h/press2-2361450.jpg)
AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024.
![](https://cdn.snapi.dev/images/v1/s/f/conf1-2355236.jpg)
AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) will announce its first quarter 2024 financial results on Tuesday, May 7, 2024, and hold an earnings conference call at...
![](https://cdn.snapi.dev/images/v1/r/h/conf12-2331806.jpg)
AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Bloom Burton Healthcare Conference on Tuesday, Apr...
![](https://cdn.snapi.dev/images/v1/c/x/press18-2317867.jpg)
AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) and Biogen Inc. (Nasdaq: BIIB) have entered into a strategic collaboration to discover antibodies for a novel target th...
![](https://cdn.snapi.dev/images/v1/t/t/press15-2309696.jpg)
AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced that its scientists will present four posters with data from its T-cell engager programs and platform a...
![](https://cdn.snapi.dev/images/v1/l/k/press6-2291887.jpg)
AbCellera Announces Resignation of Board Member
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced that Peter Thiel has notified the Company of his intention to resign from the Company's Board of Direct...
![](https://cdn.snapi.dev/images/v1/4/j/conf13-2290308.jpg)
AbCellera to Present at Upcoming Investor Conferences in March
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following investor conferences: 44th Annual TD Cow...
![](https://cdn.snapi.dev/images/v1/s/c/press10-2284647.jpg)
AbCellera Reports Full Year 2023 Business Results
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced financial results for the full year 2023. All financial information in this press release is reported i...
![](https://cdn.snapi.dev/images/v1/o/x/conf5-2241191.jpg)
AbCellera to Report Full Year 2023 Financial Results on February 20, 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) will announce its full year 2023 financial results on Tuesday, February 20, 2024, and hold an earnings conference call ...
![](https://cdn.snapi.dev/images/v1/x/s/conf13-2204196.jpg)
AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference on W...
![](https://cdn.snapi.dev/images/v1/w/o/conf11-2162315.jpg)
AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023.
![](https://cdn.snapi.dev/images/v1/z/v/press3-2139485.jpg)
AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023.
![](https://cdn.snapi.dev/images/v1/h/p/press13-2137689.jpg)
AbCellera Reports Q3 2023 Business Results
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q3 2023 Business Results.
![](https://cdn.snapi.dev/images/v1/v/h/press2-2134196.jpg)
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
WILMINGTON, Del. & VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology...
![](https://cdn.snapi.dev/images/v1/b/c/conf4-2131534.jpg)
AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023.
![](https://cdn.snapi.dev/images/v1/m/l/conf9-2099591.jpg)
AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023.
![](https://cdn.snapi.dev/images/v1/w/8/press2-2079794.jpg)
AbCellera Announces Two T-Cell Engager Presentations at SITC 2023
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Two T-Cell Engager Presentations at SITC 2023.
![](https://cdn.snapi.dev/images/v1/k/2/press4-2071015.jpg)
AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron.
![](https://cdn.snapi.dev/images/v1/9/6/press5-2061596.jpg)
AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology.
![](https://cdn.snapi.dev/images/v1/s/4/press19-2005619.jpg)
AbCellera Reports Q2 2023 Business Results
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q2 2023 Business Results.
![](https://cdn.snapi.dev/images/v1/g/t/press18-1985158.jpg)
AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights' Request for Rehearing
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights' Request for Rehearing.